Posts

Showing posts with the label Science

High levels of a hazardous chemical polluted the air weeks after the Ohio train derailment, an analysis shows

Image
[ad_1] General view of the site of the derailment of a train carrying hazardous waste, in East Palestine, Ohio, March 2, 2023. Alan Freed | Reuters Soon after the  derailment of a Norfolk Southern  train in East Palestine, Ohio, a team of researchers began roving the small town in a Nissan van. It was February, less than three weeks after the disaster, and the van was outfitted with an instrument called a mass spectrometer, which can measure hundreds to thousands of compounds in the air every second. The team was searching for harmful levels of air pollution. At the time, a primary concern was a flammable substance called vinyl chloride, because Norfolk Southern intentionally burned off the chemical in an attempt to avoid the chance of an explosion. Some environmental health experts thought the chemical may have contributed to the  rashes, vomiting, bloody noses and bronchitis  some residents reported. But a  new study  from the team behind the research van — a group of scientist

IIT Madras to Launch First Global Campus in Zanzibar from October with Woman Director - News18

Image
[ad_1] Applications for the 2023 batch are currently open with 50 seats for the BS course and 20 seats for the M Tech course. (File photo/Twitter) The first offshore campus of the Indian Institute of Technology has also become the first-ever IIT to have a woman director, Prof Preeti Aghalayam Indian Institute of Technology (IIT) Madras is going to launch India’s first global campus in Zanzibar-Tanzania, East Africa, on October 25, which will become the first IIT ever to be headed by a woman director. To start with, the campus will offer a BS degree in data science and AI and an M Tech degree in the same discipline. The new international campus will be headed by Prof Preeti Aghalayam, dean of the School of Science and Engineering at IIT Madras , who will now take charge of the Zanzibar campus as its director, the institute announced on Monday. The governments of India and Tanzania had last week signed an MoU to this effect. Applications for the 2023 batch are currently open with 50

Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024

Image
[ad_1] Jay Reinstein, who suffers from Alzheimer's, receives an injection so he can have a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson Chávez | The Washington Post | Getty Images Sales of the Alzheimer's drug Leqembi may be slow initially due to logistical requirements but could pick up in 2024, analysts said after the groundbreaking treatment won approval in the U.S.  Wall Street is chewing over the Food and Drug Administration 's Thursday approval of Leqembi – a milestone in the treatment of the disease , even though the drug isn't a cure.  Leqembi, from drugmakers Eisai and Biogen , is the first medicine proven to slow the progression of Alzheimer's in people at the early stages of the memory-robbing disease.  Medicare on Thursday announced it is now covering the antibody treatment for patients enrolled in the insurance program for seniors, broadening access for those who can't afford the d

FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage

Image
[ad_1] The Food and Drug Administration on Thursday fully approved the Alzheimer's treatment Leqembi, a pivotal decision that will expand access to the expensive drug for older Americans. Medicare announced shortly after the FDA approval that it is now covering the antibody treatment for patients enrolled in the insurance program for seniors, though several conditions apply. Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval. It is also the first such drug that to receive broad coverage through Medicare. Leqembi is not a cure. The treatment slowed cognitive decline from early Alzheimer's disease by 27% over 18 months during Eisai's clinical trial. The antibody, administered twice monthly through intravenous infusion, targets a protein called amyloid that is associated with Alzheimer's disease. Medicare coverage is a crucial step to help older Americans with early Alzheimer's disease pay for the treatment. With a median income

Ex-Tesla engineer builds Aigen robots to eliminate weeds without pesticides

Image
[ad_1] Aigen founders: Rich Wurden (CTO) and Kenny Lee (CEO) Courtesy: Aigen The Aigen Element looks like a drafting table on rugged tires. It drives itself continuously at around two miles per hour over farmland, using an advanced computer vision system to identify crops and unwanted botanical invaders. With two-axis robotic arms positioned close the ground, the Element can flick weeds out of the way where they'll dry out before they can grow seeds and spread. The robots, which are used in a fleet and sized to meet the needs of a particular growing operation, work continuously for 12 to 14 hours at a time and never need to be plugged in. They are equipped with a lithium iron phosphate battery pack, as well as flexible solar panels which are lighter than the kind typically used on rooftops. They can even run in the dark for about four hours, or six hours in light to moderate rain — all without the emissions associated with diesel-powered farm equipment. The company behind the

Nike CEO John Donahoe on how he manages sleep health in a hectic life

Image
[ad_1] For leaders in corporate America, sleep is often the rare luxury they don't have and can't buy. Success, especially early success, rarely comes without pulling some all-nighters, but among the market's most well-known leaders, there is recognition that burning the midnight oil is not a smart long-term strategy for productivity. "I've tried to sleep less, but even though I'm awake more hours, I get less done. And the brain pain level is bad if I get less than six hours of sleep per night," Elon Musk said in a recent interview with CNBC's David Faber. "I knew I wasn't as sharp when I was operating mostly on caffeine and adrenaline, but I was obsessed with work," Bill Gates said in a blog post back in 2019.  Nike CEO John Donahoe leads a hectic life, and deals with a wide range of issues, those both predictable, such as managing margins for a Wall Street quick to sour on any signs of financial challenges, to the geopolitics o